TABLE 1 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 2 EUROPE IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 3 EUROPE IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 4 EUROPE BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 5 EUROPE BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 6 EUROPE IMMUNOHISTOCHEMISTRY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 7 EUROPE BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 8 EUROPE BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 9 EUROPE GENETIC TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 10 EUROPE CYTOGENETICS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 11 EUROPE LUMBAR PUNCTURE (SPINAL TAP) IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 12 EUROPE BLOOD TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 13 EUROPE CYTOCHEMISTRY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 14 EUROPE OTHERS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 15 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 16 EUROPE AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 17 EUROPE AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 18 EUROPE DIFFUSE LARGE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 19 EUROPE ANAPLASTIC LARGE-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 20 EUROPE MANTLE CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 21 EUROPE PERIPHERAL T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 22 EUROPE LYMPHOBLASTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 23 EUROPE BURKITT LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 24 EUROPE INDOLENT LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 25 EUROPE AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 26 EUROPE FOLLICULAR LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 27 EUROPE CUTANEOUS T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 28 EUROPE MARGINAL ZONE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 29 EUROPE LYMPHOPLASMACYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 30 EUROPE SMALL-CELL LYMPHOCYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 31 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 32 EUROPE SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 33 EUROPE SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 34 EUROPE DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 35 EUROPE DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 36 EUROPE PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 37 EUROPE PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 38 EUROPE RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 39 EUROPE RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 40 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 41 EUROPE STAGE IV IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 42 EUROPE STAGE I IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 43 EUROPE STAGE III IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 44 EUROPE STAGE II IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION
TABLE 45 EUROPE STAGE 0 IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 46 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 47 EUROPE FLUORESCENT IN SITU HYBRIDIZATION IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 48 EUROPE NEXT GENERATION SEQUENCING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 49 EUROPE FLUORIMMUNOASSAY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 50 EUROPE COMPARATIVE GENOMIC HYBRIDIZATION IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 51 EUROPE IMMUNOHISTOCHEMICAL IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 52 EUROPE OTHERS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 53 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 54 EUROPE INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 55 EUROPE INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 56 EUROPE PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 57 EUROPE PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 58 EUROPE KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 59 EUROPE INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 60 EUROPE OTHER CONSUMABLES IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION))
TABLE 61 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 62 EUROPE HOSPITALS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 63 EUROPE DIAGNOSTIC CENTERS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 64 EUROPE CANCER RESEARCH CENTERS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 65 EUROPE ACADEMIC INSTITUTES IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 66 EUROPE AMBULATORY SURGICAL CENTERS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 67 EUROPE OTHERS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 68 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 69 EUROPE DIRECT TENDER IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 70 EUROPE RETAIL SALES IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 71 EUROPE OTHERS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 72 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 73 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 74 EUROPE IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 75 EUROPE BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 76 EUROPE BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 77 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 78 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 79 EUROPE AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 80 EUROPE DIFFUSE LARGE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 81 EUROPE ANAPLASTIC LARGE-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 82 EUROPE MANTLE CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 83 EUROPE PERIPHERAL T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 84 EUROPE LYMPHOBLASTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 85 EUROPE BURKITT LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 86 EUROPE INDOLENT LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 87 EUROPE FOLLICULAR LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 88 EUROPE CUTANEOUS T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 89 EUROPE MARGINAL ZONE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 90 EUROPE LYMPHOPLASMACYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 91 EUROPE SMALL-CELL LYMPHOCYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 92 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 93 EUROPE INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 94 EUROPE INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 95 EUROPE INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 96 EUROPE PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 97 EUROPE PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 98 EUROPE PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 99 EUROPE KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 100 EUROPE KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 101 EUROPE KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 102 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 103 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 104 EUROPE SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 105 EUROPE DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 106 EUROPE PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 107 EUROPE RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 108 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 109 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 110 GERMANY NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 111 GERMANY IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 112 GERMANY BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 113 GERMANY BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 114 GERMANY NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 115 GERMANY NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 116 GERMANY AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 117 GERMANY DIFFUSE LARGE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 118 GERMANY ANAPLASTIC LARGE-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 119 GERMANY MANTLE CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 120 GERMANY PERIPHERAL T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 121 GERMANY LYMPHOBLASTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 122 GERMANY BURKITT LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 123 GERMANY INDOLENT LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 124 GERMANY FOLLICULAR LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 125 GERMANY CUTANEOUS T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 126 GERMANY MARGINAL ZONE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 127 GERMANY LYMPHOPLASMACYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 128 GERMANY SMALL-CELL LYMPHOCYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 129 GERMANY NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 130 GERMANY INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 131 GERMANY INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 132 GERMANY INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 133 GERMANY PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 134 GERMANY PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 135 GERMANY PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 136 GERMANY KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 137 GERMANY KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 138 GERMANY KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 139 GERMANY NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 140 GERMANY NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 141 GERMANY SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 142 GERMANY DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 143 GERMANY PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 144 GERMANY RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 145 GERMANY NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 146 GERMANY NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 147 UNITED KINGDOM NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 148 UNITED KINGDOM IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 149 UNITED KINGDOM BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 150 UNITED KINGDOM BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 151 UNITED KINGDOM NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 152 UNITED KINGDOM NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 153 UNITED KINGDOM AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 154 UNITED KINGDOM DIFFUSE LARGE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 155 UNITED KINGDOM ANAPLASTIC LARGE-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 156 UNITED KINGDOM MANTLE CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 157 UNITED KINGDOM PERIPHERAL T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 158 UNITED KINGDOM LYMPHOBLASTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 159 UNITED KINGDOM BURKITT LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 160 UNITED KINGDOM INDOLENT LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 161 UNITED KINGDOM FOLLICULAR LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 162 UNITED KINGDOM CUTANEOUS T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 163 UNITED KINGDOM MARGINAL ZONE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 164 UNITED KINGDOM LYMPHOPLASMACYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 165 UNITED KINGDOM SMALL-CELL LYMPHOCYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 166 UNITED KINGDOM NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 167 UNITED KINGDOM INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 168 UNITED KINGDOM INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 169 UNITED KINGDOM INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 170 UNITED KINGDOM PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 171 UNITED KINGDOM PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 172 UNITED KINGDOM PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 173 UNITED KINGDOM KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 174 UNITED KINGDOM KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 175 UNITED KINGDOM KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 176 UNITED KINGDOM NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 177 UNITED KINGDOM NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 178 UNITED KINGDOM SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 179 UNITED KINGDOM DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 180 UNITED KINGDOM PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 181 UNITED KINGDOM RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 182 UNITED KINGDOM NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 183 UNITED KINGDOM NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 184 FRANCE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 185 FRANCE IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 186 FRANCE BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 187 FRANCE BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 188 FRANCE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 189 FRANCE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 190 FRANCE AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 191 FRANCE DIFFUSE LARGE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 192 FRANCE ANAPLASTIC LARGE-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 193 FRANCE MANTLE CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 194 FRANCE PERIPHERAL T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 195 FRANCE LYMPHOBLASTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 196 FRANCE BURKITT LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 197 FRANCE INDOLENT LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 198 FRANCE FOLLICULAR LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 199 FRANCE CUTANEOUS T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 200 FRANCE MARGINAL ZONE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 201 FRANCE LYMPHOPLASMACYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 202 FRANCE SMALL-CELL LYMPHOCYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 203 FRANCE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 204 FRANCE INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 205 FRANCE INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 206 FRANCE INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 207 FRANCE PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 208 FRANCE PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 209 FRANCE PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 210 FRANCE KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 211 FRANCE KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 212 FRANCE KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 213 FRANCE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 214 FRANCE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 215 FRANCE SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 216 FRANCE DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 217 FRANCE PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 218 FRANCE RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 219 FRANCE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 220 FRANCE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 221 ITALY NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 222 ITALY IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 223 ITALY BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 224 ITALY BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 225 ITALY NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 226 ITALY NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 227 ITALY AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 228 ITALY DIFFUSE LARGE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 229 ITALY ANAPLASTIC LARGE-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 230 ITALY MANTLE CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 231 ITALY PERIPHERAL T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 232 ITALY LYMPHOBLASTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 233 ITALY BURKITT LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 234 ITALY INDOLENT LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 235 ITALY FOLLICULAR LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 236 ITALY CUTANEOUS T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 237 ITALY MARGINAL ZONE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 238 ITALY LYMPHOPLASMACYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 239 ITALY SMALL-CELL LYMPHOCYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 240 ITALY NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 241 ITALY INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 242 ITALY INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 243 ITALY INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 244 ITALY PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 245 ITALY PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 246 ITALY PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 247 ITALY KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 248 ITALY KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 249 ITALY KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 250 ITALY NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 251 ITALY NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 252 ITALY SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 253 ITALY DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 254 ITALY PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 255 ITALY RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 256 ITALY NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 257 ITALY NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 258 SPAIN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 259 SPAIN IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 260 SPAIN BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 261 SPAIN BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 262 SPAIN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 263 SPAIN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 264 SPAIN AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 265 SPAIN DIFFUSE LARGE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 266 SPAIN ANAPLASTIC LARGE-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 267 SPAIN MANTLE CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 268 SPAIN PERIPHERAL T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 269 SPAIN LYMPHOBLASTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 270 SPAIN BURKITT LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 271 SPAIN INDOLENT LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 272 SPAIN FOLLICULAR LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 273 SPAIN CUTANEOUS T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 274 SPAIN MARGINAL ZONE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 275 SPAIN LYMPHOPLASMACYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 276 SPAIN SMALL-CELL LYMPHOCYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 277 SPAIN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 278 SPAIN INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 279 SPAIN INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 280 SPAIN INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 281 SPAIN PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 282 SPAIN PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 283 SPAIN PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 284 SPAIN KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 285 SPAIN KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 286 SPAIN KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 287 SPAIN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 288 SPAIN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 289 SPAIN SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 290 SPAIN DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 291 SPAIN PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 292 SPAIN RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 293 SPAIN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 294 SPAIN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 295 RUSSIA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 296 RUSSIA IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 297 RUSSIA BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 298 RUSSIA BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 299 RUSSIA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 300 RUSSIA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 301 RUSSIA AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 302 RUSSIA DIFFUSE LARGE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 303 RUSSIA ANAPLASTIC LARGE-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 304 RUSSIA MANTLE CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 305 RUSSIA PERIPHERAL T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 306 RUSSIA LYMPHOBLASTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 307 RUSSIA BURKITT LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 308 RUSSIA INDOLENT LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 309 RUSSIA FOLLICULAR LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 310 RUSSIA CUTANEOUS T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 311 RUSSIA MARGINAL ZONE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 312 RUSSIA LYMPHOPLASMACYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 313 RUSSIA SMALL-CELL LYMPHOCYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 314 RUSSIA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 315 RUSSIA INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 316 RUSSIA INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 317 RUSSIA INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 318 RUSSIA PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 319 RUSSIA PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 320 RUSSIA PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 321 RUSSIA KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 322 RUSSIA KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 323 RUSSIA KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 324 RUSSIA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 325 RUSSIA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 326 RUSSIA SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 327 RUSSIA DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 328 RUSSIA PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 329 RUSSIA RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 330 RUSSIA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 331 RUSSIA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 332 NETHERLANDS NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 333 NETHERLANDS IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 334 NETHERLANDS BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 335 NETHERLANDS BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 336 NETHERLANDS NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 337 NETHERLANDS NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 338 NETHERLANDS AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 339 NETHERLANDS DIFFUSE LARGE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 340 NETHERLANDS ANAPLASTIC LARGE-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 341 NETHERLANDS MANTLE CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 342 NETHERLANDS PERIPHERAL T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 343 NETHERLANDS LYMPHOBLASTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 344 NETHERLANDS BURKITT LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 345 NETHERLANDS INDOLENT LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 346 NETHERLANDS FOLLICULAR LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 347 NETHERLANDS CUTANEOUS T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 348 NETHERLANDS MARGINAL ZONE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 349 NETHERLANDS LYMPHOPLASMACYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 350 NETHERLANDS SMALL-CELL LYMPHOCYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 351 NETHERLANDS NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 352 NETHERLANDS INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 353 NETHERLANDS INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 354 NETHERLANDS INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 355 NETHERLANDS PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 356 NETHERLANDS PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 357 NETHERLANDS PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 358 NETHERLANDS KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 359 NETHERLANDS KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 360 NETHERLANDS KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 361 NETHERLANDS NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 362 NETHERLANDS NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 363 NETHERLANDS SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 364 NETHERLANDS DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 365 NETHERLANDS PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 366 NETHERLANDS RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 367 NETHERLANDS NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 368 NETHERLANDS NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 369 SWITZERLAND NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 370 SWITZERLAND IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 371 SWITZERLAND BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 372 SWITZERLAND BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 373 SWITZERLAND NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 374 SWITZERLAND NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 375 SWITZERLAND AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 376 SWITZERLAND DIFFUSE LARGE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 377 SWITZERLAND ANAPLASTIC LARGE-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 378 SWITZERLAND MANTLE CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 379 SWITZERLAND PERIPHERAL T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 380 SWITZERLAND LYMPHOBLASTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 381 SWITZERLAND BURKITT LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 382 SWITZERLAND INDOLENT LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 383 SWITZERLAND FOLLICULAR LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 384 SWITZERLAND CUTANEOUS T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 385 SWITZERLAND MARGINAL ZONE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 386 SWITZERLAND LYMPHOPLASMACYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 387 SWITZERLAND SMALL-CELL LYMPHOCYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 388 SWITZERLAND NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 389 SWITZERLAND INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 390 SWITZERLAND INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 391 SWITZERLAND INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 392 SWITZERLAND PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 393 SWITZERLAND PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 394 SWITZERLAND PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 395 SWITZERLAND KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 396 SWITZERLAND KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 397 SWITZERLAND KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 398 SWITZERLAND NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 399 SWITZERLAND NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 400 SWITZERLAND SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 401 SWITZERLAND DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 402 SWITZERLAND PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 403 SWITZERLAND RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 404 SWITZERLAND NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 405 SWITZERLAND NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 406 BELGIUM NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 407 BELGIUM IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 408 BELGIUM BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 409 BELGIUM BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 410 BELGIUM NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 411 BELGIUM NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 412 BELGIUM AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 413 BELGIUM DIFFUSE LARGE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 414 BELGIUM ANAPLASTIC LARGE-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 415 BELGIUM MANTLE CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 416 BELGIUM PERIPHERAL T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 417 BELGIUM LYMPHOBLASTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 418 BELGIUM BURKITT LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 419 BELGIUM INDOLENT LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 420 BELGIUM FOLLICULAR LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 421 BELGIUM CUTANEOUS T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 422 BELGIUM MARGINAL ZONE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 423 BELGIUM LYMPHOPLASMACYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 424 BELGIUM SMALL-CELL LYMPHOCYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 425 BELGIUM NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 426 BELGIUM INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 427 BELGIUM INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 428 BELGIUM INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 429 BELGIUM PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 430 BELGIUM PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 431 BELGIUM PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 432 BELGIUM KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 433 BELGIUM KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 434 BELGIUM KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 435 BELGIUM NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 436 BELGIUM NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 437 BELGIUM SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 438 BELGIUM DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 439 BELGIUM PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 440 BELGIUM RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 441 BELGIUM NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 442 BELGIUM NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 443 TURKEY NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 444 TURKEY IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 445 TURKEY BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 446 TURKEY BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 447 TURKEY NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 448 TURKEY NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 449 TURKEY DIFFUSE LARGE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 450 TURKEY ANAPLASTIC LARGE-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 451 TURKEY MANTLE CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 452 TURKEY PERIPHERAL T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 453 TURKEY LYMPHOBLASTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 454 TURKEY BURKITT LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 455 TURKEY INDOLENT LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 456 TURKEY FOLLICULAR LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 457 TURKEY CUTANEOUS T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 458 TURKEY MARGINAL ZONE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 459 TURKEY LYMPHOPLASMACYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 460 TURKEY SMALL-CELL LYMPHOCYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 461 TURKEY NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 462 TURKEY INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 463 TURKEY INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 464 TURKEY INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 465 TURKEY PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 466 TURKEY PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 467 TURKEY PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 468 TURKEY KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 469 TURKEY KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 470 TURKEY KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 471 TURKEY NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 472 TURKEY NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 473 TURKEY SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 474 TURKEY DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 475 TURKEY PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 476 TURKEY RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 477 TURKEY NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 478 TURKEY NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 479 REST OF EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)